Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 543
Filter
Add more filters

Publication year range
1.
Cell ; 185(11): 1807-1808, 2022 05 26.
Article in English | MEDLINE | ID: mdl-35623325

ABSTRACT

People with cystic fibrosis (CF) are commonly infected with difficult to treat organisms, including non-tuberculous mycobacteria. Bacteriophage are viruses that lyse specific bacteria. Nick and colleagues describe the first successful treatment of a Mycobacterium abscessus lung infection with bacteriophage in an immune competent individual. This report provides important information regarding the efficacy of phage therapy and timeline of treatment response.


Subject(s)
Bacteriophages , Cystic Fibrosis , Mycobacterium Infections, Nontuberculous , Phage Therapy , Pneumonia , Cystic Fibrosis/therapy , Humans , Mycobacterium Infections, Nontuberculous/therapy
2.
Cell ; 185(11): 1860-1874.e12, 2022 05 26.
Article in English | MEDLINE | ID: mdl-35568033

ABSTRACT

Two mycobacteriophages were administered intravenously to a male with treatment-refractory Mycobacterium abscessus pulmonary infection and severe cystic fibrosis lung disease. The phages were engineered to enhance their capacity to lyse M. abscessus and were selected specifically as the most effective against the subject's bacterial isolate. In the setting of compassionate use, the evidence of phage-induced lysis was observed using molecular and metabolic assays combined with clinical assessments. M. abscessus isolates pre and post-phage treatment demonstrated genetic stability, with a general decline in diversity and no increased resistance to phage or antibiotics. The anti-phage neutralizing antibody titers to one phage increased with time but did not prevent clinical improvement throughout the course of treatment. The subject received lung transplantation on day 379, and systematic culturing of the explanted lung did not detect M. abscessus. This study describes the course and associated markers of a successful phage treatment of M. abscessus in advanced lung disease.


Subject(s)
Bacteriophages , Cystic Fibrosis , Mycobacterium Infections, Nontuberculous , Mycobacterium abscessus , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacteriophages/genetics , Cystic Fibrosis/drug therapy , Humans , Lung , Male , Mycobacterium Infections, Nontuberculous/therapy , Mycobacterium abscessus/physiology
3.
J Surg Orthop Adv ; 32(1): 55-58, 2023.
Article in English | MEDLINE | ID: mdl-37185079

ABSTRACT

We present two cases of immunocompetent individuals diagnosed with nontuberculous infections of the hand caused by organisms rarely seen in the clinical setting: Mycobacterium heckeshornense and Mycobacterium chelonae. In the first case, a 50-year-old male presented with tenosynovitis of left long finger. He was subsequently found to have a Mycobacterium heckeshornense infection that was resolved with multiple surgeries and a long-term regimen of several antibiotics. The second case was a 29-year-old female with a history of a trivial hand injury infected with Mycobacterium chelonae. She was successfully treated with surgical debridement and antibiotics over the course of eight months. It is important to recognize the increasing prevalence of these two species of bacteria as human pathogens that can result in infections of the extremities even in immunocompetent individuals. (Journal of Surgical Orthopaedic Advances 32(1):055-058, 2023).


Subject(s)
Mycobacterium Infections, Nontuberculous , Mycobacterium chelonae , Mycobacterium , Male , Female , Humans , Adult , Middle Aged , Mycobacterium Infections, Nontuberculous/therapy , Mycobacterium Infections, Nontuberculous/drug therapy , Hand , Anti-Bacterial Agents/therapeutic use
4.
Retina ; 42(2): 321-327, 2022 02 01.
Article in English | MEDLINE | ID: mdl-34483314

ABSTRACT

PURPOSE: To describe the presentation, microbiology, management, and prognosis of eyes with endophthalmitis after Boston keratoprosthesis implantation. METHODS: Retrospective case series with history, diagnostics, management, and outcomes data in endophthalmitis after keratoprosthesis implantation presenting to a tertiary center between 2009 and 2020. RESULTS: Of 137 keratoprosthesis-implanted eyes, 7 eyes of 7 patients (5%) developed endophthalmitis. On presentation, 6 (86%) reported decreased visual acuity, and only 1 (14%) reported pain. Peripheral corneal ulcers were present in 2 eyes (29%). Seidel testing was negative in all cases. Six eyes (86%) had retroprosthetic membranes. One (14%) underwent initial pars plana vitrectomy with mechanical vitreous biopsy, whereas 6 (86%) received a needle vitreous tap-half of which were dry. Organisms were isolated after vitreous tap in two eyes: Streptococcus intermedius and Mycobacterium abscessus. The mean visual acuity preendophthalmitis, at presentation, and at 6 months were 20/267, 20/5,944, and 20/734, respectively. The visual acuity improved 9.08 ± 11.78 Early Treatment Diabetic Retinopathy Study lines from presentation to 6 months. Six-month visual acuity was correlated with preendophthalmitis visual acuity (r = 0.92, P = 0.003) but not presenting visual acuity (P = 0.838). CONCLUSION: Visual acuity at 6 months is correlated with preendophthalmitis visual acuity, not presenting visual acuity. Endophthalmitis should be considered in the differential diagnosis of painless intraocular inflammation any time after keratoprosthesis implantation, even if Seidel negative.


Subject(s)
Artificial Organs , Cornea , Endophthalmitis/physiopathology , Eye Infections, Bacterial/physiopathology , Postoperative Complications , Visual Acuity/physiology , Aged , Anti-Bacterial Agents/therapeutic use , Combined Modality Therapy , Drug Combinations , Endophthalmitis/microbiology , Endophthalmitis/therapy , Eye Infections, Bacterial/microbiology , Eye Infections, Bacterial/therapy , Female , Humans , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium Infections, Nontuberculous/physiopathology , Mycobacterium Infections, Nontuberculous/therapy , Mycobacterium abscessus/isolation & purification , Prostheses and Implants , Prosthesis Implantation , Retrospective Studies , Streptococcal Infections/microbiology , Streptococcal Infections/physiopathology , Streptococcal Infections/therapy , Streptococcus intermedius/isolation & purification , Vitrectomy , Vitreous Body/microbiology
5.
Pneumologie ; 76(8): 534-546, 2022 Aug.
Article in German | MEDLINE | ID: mdl-35878604

ABSTRACT

INTRODUCTION: Management of patients with lung disease caused by non-tuberculous mycobacteria (NTM-LD) in Germany is currently characterized by delayed diagnosis, frequently poor prognosis and high follow-up costs. Mainly due to an increased number of hospitalizations, the SHI-relevant direct costs (€ 9,093.20 patient/year) are higher compared to typical underlying diseases (e.g. asthma: € 706.00 patient/year). This less than optimal NTM care is mainly caused by lack of awareness of the disease at primary care and out-patient specialist care level, largely absent structured referral structures and limited communication between specialists out of hospital with specialized NTM clinics. Lack of incentives to support these communication pathways is part of the problem. Sufficient, appropriate and economically sustainable care is hampered by poor adherence to treatment recommendations. METHODS: For the development of the NTM care concept, relevant professional societies and patient organizations were interviewed about the care situation. Thereafter, 20 NTM-LD patients, 5 residential pulmonologists and 8 experts were interviewed in an explorative qualitative interview to determine the current patient pathway. Based on the findings, the NTM care concept was developed in an advisory board by the authors. RESULTS: Regional management centers should concentrate specific expertise and ensure quality of care through routine consultation and involvement in diagnosis, decision-making on treatment necessity, initiation of therapy, follow-up examinations, and determination of the therapy success, as well as adequate follow-up of patients. The referring pulmonologist should continue to provide case-specific therapy support close to the patient's home in preferred shared-care concept. The establishment of clear referral structures and case identification criteria will help residential physicians to include patients at risk in the NTM-care system early. Patients and pulmonologists without specific expertise need to be made aware of the care pathway and severity of NTM-LD. CONCLUSION: The increased morbidity and mortality of NTM-LD patients must be addressed with patient-oriented, interdisciplinary and trans-sectoral care concept. An NTM care system with clear treatment procedures and referral structures is proposed for a nationwide pilot project.


Subject(s)
Lung Diseases , Mycobacterium Infections, Nontuberculous , Hospitalization , Humans , Lung Diseases/diagnosis , Lung Diseases/microbiology , Lung Diseases/therapy , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/therapy , Nontuberculous Mycobacteria , Pilot Projects
6.
Eur J Clin Microbiol Infect Dis ; 40(2): 247-254, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32875518

ABSTRACT

The clinical importance of Mycobacterium abscessus subsp. abscessus (M. abscessus) lung disease has been increasing, but few studies have assessed the clinical characteristics associated with the treatment outcome. We retrospectively analyzed 75 consecutive patients with M. abscessus lung disease diagnosed at a tertiary hospital from January 2004 to April 2018. Among 52 patients with sufficient clinical data, 19 patients (42.2%) achieved treatment success. Compared with 26 (57.8%) patients in the treatment failure group, body mass index (BMI) (19.8 vs 17.5 kg/m2, P = 0.022), previous nontuberculous mycobacterial (NTM) lung disease (26.3% vs 61.5%, P = 0.034), the presence of cavitary lesions (31.6% vs 69.2%, P = 0.017), and the bronchiectasis score (3.0 vs 5.0, P = 0.003) were significantly different in the treatment success group. Multivariate analysis showed that age (adjusted hazard ratio (aHR), 0.94; 95% confidence interval (CI), 0.90 to 0.99; P = 0.010), the presence of cavitary lesions (aHR, 0.34; 95% CI, 0.12 to 0.94; P = 0.039), and previous NTM lung disease (aHR, 0.28; 95% CI, 0.09 to 0.86; P = 0.026) were negatively associated with treatment success. This is the first study to show that previous NTM lung disease might be a clinically important factor related to unfavorable treatment outcomes in M. abscessus lung disease patients. To increase our understanding the characteristics of M. abscessus lung disease, this factor should be independently analyzed in future research.


Subject(s)
Lung Diseases/therapy , Mycobacterium Infections, Nontuberculous/therapy , Aged , Female , Humans , Lung Diseases/microbiology , Male , Middle Aged , Retrospective Studies , Risk Factors , Treatment Failure
7.
BMC Infect Dis ; 21(1): 698, 2021 Jul 20.
Article in English | MEDLINE | ID: mdl-34284734

ABSTRACT

BACKGROUND: The incidence and prevalence of non-tuberculous mycobacterial pulmonary disease (NTM-PD) are reportedly increasing in many parts of the world. However, there are few published data on NTM-PD-related death. Using data from a national inpatient database in Japan, we aimed in this study to identify the characteristics of patients with NTM-PD and clinical deterioration and to identify risk factors for in-hospital mortality. METHODS: We examined data from the Diagnosis Procedure Combination (DPC) database in Japan from July 2010 to March 2014. We extracted data for HIV-negative NTM-PD patients who required unscheduled hospitalization. We evaluated these patients' characteristics and performed multivariable logistic regression analysis to identify risk factors for all-cause in-hospital mortality. RESULTS: A total of 16,192 patients (median age: 78 years; women: 61.2%) were identified. The median body mass index (BMI) was 17.5 kg/m2 (IQR 15.4-20.0). All cause In-hospital death occurred in 3166 patients (19.6%). The median BMI of the patients who had died was 16.0 kg/m2 (IQR 14.2-18.4). Multivariable analysis revealed that increased mortality was associated with male sex, lower BMI, lower activities of daily living scores on the Barthel index, hemoptysis, and comorbidities, including pulmonary infection other than NTM, interstitial lung disease, pneumothorax, and malignant disease. CONCLUSIONS: We found associations between being underweight and having several comorbidities and increased in-hospital mortality in patients with NTM-PD. Preventing weight loss and management of comorbidities may have a crucial role in improving this disease's prognosis.


Subject(s)
Hospital Mortality , Lung Diseases/mortality , Mycobacterium Infections, Nontuberculous/mortality , Aged , Aged, 80 and over , Comorbidity , Databases, Factual , Female , Humans , Japan/epidemiology , Lung Diseases/microbiology , Lung Diseases/therapy , Male , Mycobacterium Infections, Nontuberculous/therapy , Prognosis , Risk Factors
8.
Psychol Health Med ; 26(9): 1172-1179, 2021 10.
Article in English | MEDLINE | ID: mdl-32966109

ABSTRACT

The objective of this study was to administer commonly used tools, the Center for Epidemiological Studies Depression Scale (CES-D) and the Hospital Anxiety and Depression Scale - Depression subscale (HADS-D), to screen for depressive symptoms in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). In addition, we sought to identify whether differences existed in the prevalence of depressive symptoms as assessed by CES-D and HADS-D, and by various predictors of depression. The presence of depressive symptoms in 95 patients with NTM-PD was assessed using the CES-D and HADS-D. Data regarding age, body mass index, pulmonary function, dyspnea, cough, and exercise capacity were obtained to examine their independent contribution as predictors of depressive symptoms. The prevalence of depressive symptoms was 37.9% based on CES-D and 26.3% based on HADS-D. The prevalence of depressive symptoms based on CES-D and HADS-D revealed significant differences between the two instruments. Analysis suggested that the presence of cough is a significant predictor of depressive symptoms as assessed by both CES-D and HADS-D. Countermeasures are necessary because some patients with NTM-PD disease have depressive symptoms. It is possible that assessment of the prevalence of depressive symptoms differs in accordance with the screening tool used.


Subject(s)
Depression , Lung Diseases , Mycobacterium Infections, Nontuberculous , Depression/epidemiology , Humans , Japan/epidemiology , Lung Diseases/psychology , Lung Diseases/therapy , Mycobacterium Infections, Nontuberculous/psychology , Mycobacterium Infections, Nontuberculous/therapy , Prevalence , Risk Factors
9.
J Clin Immunol ; 40(7): 1045-1047, 2020 10.
Article in English | MEDLINE | ID: mdl-32696284

ABSTRACT

This is a report of a successful bone marrow transplant in an IFN-γR1 patient with progressive mycobacterial infection. PURPOSE: Hematopoietic cell transplant in patients with interferon gamma receptor deficiencies has been fraught with challenges, not the least of which is failure of engraftment and infectious complications. METHODS: This is a report of a successful hematopoietic cell transplant in an actively infected patient of advanced age. RESULTS: This case report shows successful engraftment and resolution of infection posttransplant using a matched related donor in a single institution. CONCLUSION: A successful curative HCT despite persistent, disseminated, nontuberculous mycobacterial infection in a patient with AD-IFNγR1 suggests that this approach, while difficult, may be useful in other patients with otherwise refractory disease.


Subject(s)
Bone Marrow Transplantation , Genes, Dominant , Genetic Association Studies , Genetic Predisposition to Disease , Receptors, Interferon/deficiency , Hematopoietic Stem Cell Transplantation , Humans , Mycobacterium Infections/diagnosis , Mycobacterium Infections/etiology , Mycobacterium Infections/therapy , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/etiology , Mycobacterium Infections, Nontuberculous/therapy , Severity of Illness Index , Transplantation, Homologous , Treatment Outcome , Interferon gamma Receptor
10.
Dermatol Surg ; 46(1): 116-121, 2020 01.
Article in English | MEDLINE | ID: mdl-30964788

ABSTRACT

BACKGROUND: Nontuberculous mycobacterium (NTM) infection following cosmetic procedures usually results from inadequate sterile techniques and contamination from nonsterile water. These infections are difficult to diagnose and treat. OBJECTIVE: This study aimed to describe the characteristics of NTM infections acquired after an aesthetic procedure, identify high-risk patients and high-risk cosmetic procedures, and provide a diagnostic and management algorithm for NTM infections occurring after cosmetic procedures. METHODS: On December 20, 2017 an online search of the Medline database was done. All articles describing NTM infection in cosmetic procedures were included in this review. RESULTS: In total, 92 patients with a mean age of 38.35 years were included in this review. Cosmetic procedures performed in the Dominican Republic were the most common source of infection and were noted in 33 patients. The procedure that resulted in the highest proportion of the infections was mesotherapy (34%). In most of the cases, the diagnosis was missed at the initial presentation and a short course of inadequate antibiotics was unsuccessful. CONCLUSION: Nontuberculous mycobacterium infections are hard to diagnose and difficult to treat, sometimes leading to severe irreversible sequalae. Aesthetic practitioners should know when to suspect and how to prevent, diagnose, and treat NTM infections.


Subject(s)
Algorithms , Cosmetic Techniques/adverse effects , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/therapy , Humans , Mycobacterium Infections, Nontuberculous/etiology
11.
J Card Surg ; 35(5): 1138-1141, 2020 May.
Article in English | MEDLINE | ID: mdl-32253770

ABSTRACT

Left ventricular assist devices (LVADs) are integral for the management of medically refractory heart failure, and LVAD infections are common following device placement. Most infections are caused by Staphylococcal spp. and Gram-negative enteric bacteria but nontuberculous mycobacterial (NTM) infections have been reported. We present the second-ever reported case of a driveline infection caused by Mycobacterium fortuitum in a 75-year-old male with a continuous-flow LVAD. After receiving meropenem, azithromycin, and ciprofloxacin, he underwent device exchange and ultimately died after failing to recover neurologically. Management of NTM infections presents a clinical challenge due to the propensity for rapidly growing mycobacterial species to form biofilms and the possibility of negative cultures delaying diagnosis. To address the literature gap surrounding NTM infections in LVAD patients, we performed a systematic review and present all previously reported cases.


Subject(s)
Heart Failure/therapy , Heart-Assist Devices/adverse effects , Mycobacterium Infections, Nontuberculous/etiology , Mycobacterium Infections, Nontuberculous/therapy , Prosthesis-Related Infections/etiology , Prosthesis-Related Infections/therapy , Aged , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Ciprofloxacin/therapeutic use , Device Removal , Fatal Outcome , Humans , Male , Meropenem/therapeutic use , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium fortuitum , Prosthesis-Related Infections/microbiology
12.
J Formos Med Assoc ; 119 Suppl 1: S42-S50, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32499207

ABSTRACT

Patients with nontuberculous mycobacterial lung disease (NTM-LD) often have significant exercise intolerance and poorer health-related quality of life (HRQL). The goals of treatment for NTM-LD should include reducing the severity of symptoms, improving HRQL, and reducing acute exacerbations. Nonpharmacological treatment, including pulmonary rehabilitation program and optimal nutritional strategy, should be one part of treatment for NTM-LD. A pulmonary rehabilitation (PR) program can comprise education, airway clearance techniques instruction, exercise training program, and inspiratory muscle training (IMT). Airway clearance techniques can improve the volume of sputum expectorated, cough symptom, breathlessness, and HRQL. Exercise training can improve exercise capacity and HRQL, and reduce acute exacerbations and dyspnea. Clinical benefits of IMT remain controversial but high-intensity IMT has been shown to be effective in increasing respiratory muscle strength with concurrent improvement of HRQL and exercise capacity. Body weight and muscle mass loss are common in patients with NTM-LD. An adequate protein and caloric diet combined with antioxidant nutrients might be the most appropriate dietary strategy. Comprehensive treatment for NTM-LD should include the combination of both pharmacological and nonpharmacological treatments. The management programs should be tailored to the individual's condition.


Subject(s)
Mycobacterium Infections, Nontuberculous , Pneumonia , Dyspnea , Humans , Mycobacterium Infections, Nontuberculous/therapy , Quality of Life , Sputum
13.
J Formos Med Assoc ; 119 Suppl 1: S23-S31, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32482607

ABSTRACT

The lungs are the most common disease site of nontuberculous mycobacteria (NTM). However, the isolation of NTM in a respiratory specimen does not indicate lung disease (LD). Differentiation between NTM colonization and NTM-LD remains challenging. In this brief review, we summarize the clinical impact of NTM-LD on morbidity and mortality in high-risk populations. The diagnosis criteria for NTM-LD-including clinical features, radiological presentations, and microbiological evidence-are also reviewed, according to the latest American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) guideline and the British Thoracic Society (BTS) guideline. However, the diagnosis of NTM-LD does not necessitate the initiation of anti-NTM treatment. Both environmental, host, and bacterial factors should be considered to identify patients that require NTM-LD treatment.


Subject(s)
Lung Diseases , Mycobacterium Infections, Nontuberculous , Humans , Lung/diagnostic imaging , Lung Diseases/diagnosis , Lung Diseases/therapy , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/epidemiology , Mycobacterium Infections, Nontuberculous/therapy , Nontuberculous Mycobacteria , Risk Factors
14.
Int J Mol Sci ; 21(18)2020 Sep 16.
Article in English | MEDLINE | ID: mdl-32948001

ABSTRACT

Mycobacterium abscessus is a non-tuberculous mycobacterium notoriously known for causing severe, chronic infections. Treatment of these infections is challenging due to either intrinsic or acquired resistance of M. abscessus to multiple antibiotics. Despite prolonged poly-antimicrobial therapy, treatment of M. abscessus infections often fails, leading to progressive morbidity and eventual mortality. Great research efforts are invested in finding new therapeutic options for M. abscessus. Clofazimine and rifabutin are known anti-mycobacterial antibiotics, repurposed for use against M. abscessus. Novel antimicrobials active against M. abscessus include delamanid, pretomanid and PIPD1 and the recently approved beta-lactamase inhibitors avibactam, relebactam and vaborbactam. Previously unused antimicrobial combinations, e.g. vancomycin-clarithromycin and dual beta-lactam therapy, have been shown to have synergistic effect against M. abscessus in experimental models, suggesting their possible use in multiple-drug regimens. Finally, engineered phage therapy has been reported to be clinically successful in a severe case of disseminated M. abscessus infection. While many of these experimental therapeutics have shown activity against M. abscessus in vitro, as well as in intracellular and/or animal models, most have little if any evidence of effect in human infections. Clinical studies of M. abscesssus treatments are needed to reliably determine the value of their incorporation in therapeutic regimens.


Subject(s)
Mycobacterium Infections, Nontuberculous/therapy , Mycobacterium abscessus/drug effects , Therapies, Investigational , Administration, Inhalation , Animals , Anti-Bacterial Agents/therapeutic use , Clinical Trials as Topic , Drug Evaluation, Preclinical , Drugs, Investigational/therapeutic use , Humans , Mice , Mycobacterium Infections, Nontuberculous/drug therapy , Nitric Oxide/administration & dosage , Nitric Oxide/therapeutic use , Phage Therapy , Zebrafish
15.
Eur Respir J ; 54(1)2019 07.
Article in English | MEDLINE | ID: mdl-31221809

ABSTRACT

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a challenging infection which is becoming increasingly prevalent, particularly in the elderly, for reasons which are unknown. While underlying lung disease is a well-established risk factor for NTM-PD, it may also occur in apparently healthy individuals. No single common genetic or immunological defect has been identified in this group, and it is likely that multiple pathways contribute towards host susceptibility to NTM-PD which further interact with environmental and microbiological factors leading to the development of disease.The diagnosis of NTM-PD relies on the integration of clinical, radiological and microbiological results. The clinical course of NTM-PD is heterogeneous, with some patients remaining stable without the need for treatment and others developing refractory disease associated with considerable mortality and morbidity. Treatment regimens are based on the identity of the isolated species, drug sensitivity testing (for some agents) and the severity of disease. Multiple antibiotics are typically required for prolonged periods of time and treatment is frequently poorly tolerated. Surgery may be beneficial in selected cases. In some circumstances cure may not be attainable and there is a pressing need for better regimens to treat refractory and drug-resistant NTM-PD.This review summarises current knowledge on the epidemiology, aetiology and diagnosis of NTM-PD and discusses the treatment of two of the most clinically significant species, the M. avium and M. abscessus complexes, with a focus on refractory disease and novel therapies.


Subject(s)
Lung Diseases/therapy , Mycobacterium Infections, Nontuberculous/therapy , Antitubercular Agents/therapeutic use , Humans , Lung Diseases/diagnosis , Lung Diseases/epidemiology , Lung Diseases/microbiology , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/epidemiology , Pneumonectomy , Recurrence
16.
Transpl Infect Dis ; 21(1): e12999, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30203904

ABSTRACT

Good outcomes with kidney and liver transplantation in HIV-positive patients have led clinicians to recommend lung transplantation in HIV-positive patients based on extrapolated data. Pre-transplant mycobacterial infection is associated with an increased risk of developing new infection or aggravating existing infection, though it does not contraindicate transplantation in non-HIV-infected patients. However, no data exists regarding the outcome of HIV-positive patients with pre-transplant mycobacterial infection. We report a case of double lung transplantation in a 50-year-old HIV-positive patient with alpha-1 antitrypsin deficiency. Prior to transplantation, Mycobacterium kansasii was isolated in one sputum culture and the patient was considered merely colonized as no clinical evidence of pulmonary or disseminated disease was present. The patient successfully underwent a double lung transplantation. Nontuberculous mycobacterial infection was diagnosed histologically on examination of native lungs. Surveillance and watchful waiting were chosen over treatment of the infection. HIV remained under control post-transplantation with no AIDS-defining illnesses throughout the follow-up. A minimal acute rejection that responded to increased corticosteroids was reported. At 12 months post-transplant, a bronchiolitis obliterans syndrome was diagnosed after a drop in FEV1. No evidence of isolation nor recurrence of nontuberculous mycobacteria was reported post-transplantation. At 15 months post-transplant, the patient remained stable with an FEV1 of 30%. The presence of pre-transplant nontuberculous mycobacterial infection did not translate into recurrence of nontuberculous mycobacterial infection post-transplant. Whether it contributed to bronchiolitis obliterans syndrome remains unknown.


Subject(s)
Anti-Retroviral Agents/therapeutic use , HIV Infections/drug therapy , Lung Transplantation , Mycobacterium Infections, Nontuberculous/therapy , Mycobacterium kansasii/isolation & purification , alpha 1-Antitrypsin Deficiency/surgery , Aged , Anti-Bacterial Agents/therapeutic use , Comorbidity , HIV/drug effects , HIV/isolation & purification , HIV Infections/complications , HIV Infections/virology , Humans , Lung/diagnostic imaging , Lung/microbiology , Lung/surgery , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium Infections, Nontuberculous/diagnostic imaging , Mycobacterium Infections, Nontuberculous/microbiology , Tomography, X-Ray Computed , Treatment Outcome , Viral Load/drug effects , alpha 1-Antitrypsin Deficiency/complications , alpha 1-Antitrypsin Deficiency/diagnostic imaging
17.
Paediatr Respir Rev ; 29: 42-52, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30473423

ABSTRACT

Non-tuberculous mycobacterial (NTM) (especially M. abscessus complex) infections pose a considerable challenge in the management of lung disease in patients with cystic fibrosis (CF). The apparent increase in prevalence is likely multifactorial. Emergent evidence of patient-to-patient transmission and isolation of highly resistant strains is a concern for all CF centers around the world. Treatment is often long and burdensome with multiple agents. Treatment side effects are frequent and can cause significant morbidity. Although consensus guidelines provide some direction, many units are faced with the challenges of: finding drug combinations for highly resistant strains; dealing with interruptions of treatment; discussing additional facilitating procedures in the form of gastrostomy and long-term vascular access devices; as well as supporting families emotionally and psychologically through the process.


Subject(s)
Cystic Fibrosis/epidemiology , Mycobacterium Infections, Nontuberculous/epidemiology , Anti-Bacterial Agents/therapeutic use , Child , Cystic Fibrosis/therapy , Humans , Lung Transplantation , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/therapy , Mycobacterium abscessus , Nontuberculous Mycobacteria , Prevalence
18.
BMC Cardiovasc Disord ; 19(1): 53, 2019 03 05.
Article in English | MEDLINE | ID: mdl-30836955

ABSTRACT

BACKGROUND: With the rising utilization of cardiovascular implantable electronic devices (CIEDs), infections secondary to device implantation are increasingly encountered. Staphylococcus aureus and coagulase-negative staphylococci are usually the predominant causative organisms. A CIED infection due to non-tuberculous mycobacteria (NTM) is extremely rare. CASE PRESENTATION: A 68-year-old man was admitted to our hospital with a history of pain and swelling at his cardiac resynchronization therapy-defibrillator (CRT-D) pocket site, for 4 days. The CRT-D had been implanted 2 weeks prior. The exudate smear was positive for acid-fast bacilli and culture results revealed rapidly growing nontuberculous mycobacteria (RGM). After an urgent removal of the device followed by 1 year of antibiotic treatment, the patient was completely cured. A new device was finally implanted, 3 years later. CONCLUSIONS: Infections caused by nontuberculous mycobacteria following the implantation of cardiac devices are very rare. The typical manifestations of post-implantation CIED infections caused by RGMs include an early onset, with local redness, swelling, and spontaneous drainage. Systemic symptoms such as fever, chills, and fatigue are absent. Mycobacterium fortuitum is the most common species of RGM implicated in CIED infections, the manifestations of which usually appear within several weeks of the implantation procedure. An urgent removal of the device and appropriate antibiotic therapy are essential therapeutic measures. This is the first such reported case, in which the patient has been re-implanted with another device at the same site, after achieving a complete cure. We followed-up the patient for an additional 3 years and observed that the patient remained free of infection. Our case report shows that though an RGM infection is rare and difficult to treat, it can be completely cured. In addition, we demonstrated that it is subsequently possible to safely re-implant a CIED for the patient, at the same site.


Subject(s)
Cardiac Resynchronization Therapy Devices/adverse effects , Cardiac Resynchronization Therapy , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium fortuitum/isolation & purification , Aged , Anti-Bacterial Agents/administration & dosage , Device Removal , Humans , Male , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/therapy , Treatment Outcome
19.
Rheumatol Int ; 39(10): 1783-1787, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31352560

ABSTRACT

To investigate the clinical manifestations and outcomes of musculoskeletal (MSK) nontuberculous mycobacterium (NTM) infections. This study was a retrospective cohort study using the Siriraj Hospital database from 2005 to 2017. Enrolled were all patients aged 15 or older who had an MSK infection with NTM identified in synovial fluid, pus, or tissue by an acid-fast bacilli stain, culture, or polymerase chain reaction. Of 1529 cases who were diagnosed with NTM infections, 39 (2.6%) had an MSK infection. However, only 28 patients met our inclusion criteria. Their mean age (SD) was 54.1 (16.1) years, and half were male. Of this cohort, 25% had previous musculoskeletal trauma, 18% prior bone and joint surgery, 14% prosthetic joint replacement, and 11% HIV infection. The median symptom duration (IQR) was 16 (37.4) weeks. The most common MSK manifestation was arthritis (61%), followed by osteomyelitis (50%), tenosynovitis (25%), and spondylodiscitis (14%). The most common organism was M. abscessus (18%), and M. kansasii (18%), followed by M. intracellulare (14%), M. marinum (14%), M. fortuitum (7%), and M. haemophilum (7%). In addition to medical treatment, most patients underwent surgery (82%), comprising debridement, osteotomy, prosthesis removal, and amputation, while 18% received only medical treatment. The treatment outcomes were complete recovery in 46%, improvement with some residual disability and deformities in 29%, and death in 3.6%. Musculoskeletal NTM infections were uncommon. Most patients had underlying joint disease or were immunocompromised hosts. Surgical management, as an adjunct to medical therapy, was necessary.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/therapy , Discitis/therapy , Mycobacterium Infections, Nontuberculous/therapy , Nontuberculous Mycobacteria/drug effects , Orthopedic Procedures , Osteomyelitis/therapy , Tenosynovitis/therapy , Adult , Aged , Anti-Bacterial Agents/adverse effects , Arthritis, Infectious/diagnosis , Arthritis, Infectious/microbiology , Arthritis, Infectious/mortality , Combined Modality Therapy , Databases, Factual , Discitis/diagnosis , Discitis/microbiology , Discitis/mortality , Female , Humans , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium Infections, Nontuberculous/mortality , Nontuberculous Mycobacteria/isolation & purification , Orthopedic Procedures/adverse effects , Osteomyelitis/diagnosis , Osteomyelitis/microbiology , Osteomyelitis/mortality , Recovery of Function , Remission Induction , Retrospective Studies , Risk Factors , Tenosynovitis/diagnosis , Tenosynovitis/microbiology , Tenosynovitis/mortality , Thailand , Time Factors , Treatment Outcome
20.
South Med J ; 112(4): 217-221, 2019 04.
Article in English | MEDLINE | ID: mdl-30943540

ABSTRACT

Mycobacterium fortuitum is a rare, opportunistic pathogen most frequently contracted through contact with a contaminated source. An immunocompetent 26-year-old female patient presented to our institution with an infected lumboperitoneal (LP) shunt presenting as continued nonhealing wounds. After multiple debridements, shunt revisions, and wound closure failures, infectious disease specialists were consulted. The wound cultures returned positive for M. fortuitum and the shunt was removed. Cerebrospinal fluid studies revealed significant pleocytosis with normal opening pressure, and the patient was diagnosed as having secondary meningitis. After shunt removal, the patient was treated with intravenous and oral antibiotics, resulting in infection resolution. Five months later, a new LP shunt was placed without infection recurrence. Although M. fortuitum was previously reported in neurosurgical patients with ventriculoperitoneal shunts, which are summarized here, to date this is the first case in the literature of M. fortuitum meningitis from an LP shunt. This case demonstrates the importance of clinicians considering uncommon and slow-growing pathogens, as well as consulting infectious disease specialists for patients with persistent, unexplained infections.


Subject(s)
Catheter-Related Infections/diagnosis , Cerebrospinal Fluid Shunts , Meningitis, Bacterial/diagnosis , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium fortuitum , Pseudotumor Cerebri/surgery , Adult , Amikacin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Catheter-Related Infections/therapy , Device Removal , Female , Humans , Imipenem/therapeutic use , Immunocompetence , Meningitis, Bacterial/therapy , Mycobacterium Infections, Nontuberculous/therapy
SELECTION OF CITATIONS
SEARCH DETAIL